Kabra Drugs Ratios

Kabra Drugs Ltd Ratios

The Kabra Drugs Ltd Ratios page provides a complete fundamental analysis of Kabra Drugs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Kabra Drugs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Kabra Drugs Ltd (NSE: , BSE: 524322) is currently trading at ₹27.04, with a market capitalization of ₹0. As a major player in the Health technology sector and Pharmaceuticals: generic industry, Kabra Drugs Ltd remains a key stock for fundamental analysis using Kabra Drugs Ltd Ratios.

Kabra Drugs Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Kabra Drugs Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Kabra Drugs Ltd Ratios.

Historically, the Kabra Drugs Ltd P/E ratio has shown strong fluctuations:

The decline in Kabra Drugs Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Kabra Drugs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

Kabra Drugs Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Kabra Drugs Ltd P/S ratio currently stands at 0, an important part of Kabra Drugs Ltd Ratios for revenue valuation.

Historical P/S ratio:

A stable or declining Kabra Drugs Ltd P/S ratio indicates cautious market sentiment.

Kabra Drugs Ltd Price to Cash Flow Ratio (P/CF)

The Kabra Drugs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Kabra Drugs Ltd Price to Cash Flow Ratio:

The declining Kabra Drugs Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Kabra Drugs Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Kabra Drugs Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

Kabra Drugs Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Kabra Drugs Ltd EV/EBITDA ratio is currently 0, a key metric in Kabra Drugs Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

Stable Kabra Drugs Ltd EV/EBITDA indicates balanced valuation.

Kabra Drugs Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Kabra Drugs Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

Kabra Drugs Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Kabra Drugs Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

Declining ROE indicates pressure on profitability.

Kabra Drugs Ltd Ratios Analysis Summary

The Kabra Drugs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Kabra Drugs Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Kabra Drugs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.